This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Careful with the language on amylin analogue mechanism. "Not detected" and "not present" are different findings and the first is a statement about the method.
Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection.
Happy to be corrected if someone holds better data than mine.
Comparing an amylin analogue to an incretin agonist on weight change alone misses that they were developed to be used together rather than instead of each other.
I would not lead a decision with this, but I would not ignore it either.
The thing about amylin analogue mechanism that took me longest to accept is that a plausible mechanism is not evidence of an effect. It is a reason to look, not a result.
Adding the measurement that post #34 says would settle it.
Posting my amylin analogue mechanism numbers with the method attached so they can be discounted properly. Uncontrolled, unblinded, and collected by someone who wanted a particular answer.
Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct mechanisms. Whether the slowing at a higher magnitude produces disproportionate nausea or is tolerable is a question phase 3 exists to answer.
Adding it in case it saves somebody the afternoon it cost me.
Historical amylin analogues: pramlintide was the only long-acting amylin analogue licensed for some time and its poor adherence was a known limitation. A weekly formulation addresses that practical barrier.
Adding it because I spent an afternoon working it out and nobody should have to twice.
Answering the question post #37 raises rather than the one it answers.
Is synergy the right word for the combination data? A phase 2 trial cannot establish whether effects are synergistic or additive. Synergy is a mechanistic claim that requires a designed experiment to support it. The combination works, but the mechanism is unsettled.
For anyone finding this later: the short answer on amylin analogue mechanism is that it depends on one thing, and the rest of the thread is people identifying which thing.
For anyone arriving from searches on "amylin agonist": this subcategory discusses published clinical evidence and what it does and does not establish. It does not endorse or recommend the compounds discussed.
The literature is thinner on this than the confidence in the thread implies.
Adding the measurement that post #45 says would settle it.
Two things can be true about amylin analogue mechanism at once: the mechanism is plausible and the evidence for the size of the effect is thin. Most of the argument here is people defending the first against attacks on the second.
Where I part company with post #45, and it is a narrow parting.
On analysis: an amylin analogue and its aggregates are not equally detectable by a standard reversed-phase method, because a large aggregate may not elute at all. Area percent cannot see what stays on the column.
What is genuinely unknown about long-term amylin agonism: real-world response rates, whether effect is durable with continued use, whether satiety adaptation occurs over months or years, safety profile in populations not enrolled in the trials.
On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.
That is all I can say without guessing.
Post #48 answers the question as asked. The question underneath it is different.
Summarising the amylin analogue mechanism thread so far, since it is long and the answer is buried: the first reply has the method, the fourth has the correction to it, and the rest is people agreeing at length.
I read post #50 twice before replying, because I had assumed the opposite.
Anyone submitting this for independent testing should say in the submission that it is an amylin analogue rather than an incretin. Method selection differs and a default incretin gradient is not necessarily the right one.
I have left out the parts I could not verify.
One more thing on amylin analogue mechanism that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the apparent contradiction disappears.
Narrowing post #52, because the general version has more than one answer.
Nausea profile of amylin analogues: the historical agent pramlintide required multiple daily doses and had a difficult tolerability profile. A weekly formulation is a substantially different proposition and data from that is more relevant than data from pramlintide.
This has been discussed before and I could not find the thread, so, again.
Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS.
It is a small point and it changes the answer, which is an awkward combination.
Cagrilintide is a long-acting amylin analogue, which puts it in a different mechanistic family from the incretin agonists it is usually discussed alongside. Amylin signalling contributes to satiety through a distinct pathway.
Useful. I had the fact and not the reason, which turns out to be the important half.
I read the earlier replies on amylin analogue mechanism twice before writing this, because I had assumed the opposite and wanted to be sure I was disagreeing with what was said rather than what I expected.